About inflarx nv - IFRX
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
IFRX At a Glance
InflaRx NV
Winzerlaer Strasse 2
Jena, Thueringen 07745
| Phone | 49-36-41-508180 | Revenue | 33.10K | |
| Industry | Biotechnology | Net Income | -51,501,277.91 | |
| Sector | Health Technology | Employees | 65 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
IFRX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2,053.065 |
| Price to Book Ratio | 1.496 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.254 |
| Enterprise Value to Sales | 436.647 |
| Total Debt to Enterprise Value | 0.073 |
IFRX Efficiency
| Revenue/Employee | 509.266 |
| Income Per Employee | -792,327.352 |
| Receivables Turnover | 0.02 |
| Total Asset Turnover | 0.00 |
IFRX Liquidity
| Current Ratio | 4.132 |
| Quick Ratio | 4.132 |
| Cash Ratio | 3.579 |
IFRX Profitability
| Gross Margin | -26,015.489 |
| Operating Margin | -173,591.67 |
| Pretax Margin | -155,540.207 |
| Net Margin | -155,582.08 |
| Return on Assets | -71.746 |
| Return on Equity | -91.637 |
| Return on Total Capital | -103.29 |
| Return on Invested Capital | -90.696 |
IFRX Capital Structure
| Total Debt to Total Equity | 2.161 |
| Total Debt to Total Capital | 2.115 |
| Total Debt to Total Assets | 1.626 |
| Long-Term Debt to Equity | 1.542 |
| Long-Term Debt to Total Capital | 1.51 |